US 2003/0118575 A1Published application

Method for administering BIRB 796 BS

AssigneeBoehringer Ingelheim Pharmaceuticals, Inc.

InventorsPeter M. Grob, Jeffrey B. Madwed, Christopher Pargellis, Chan Loi Yong

Life of this patent

Estimating the term…

Abstract

Disclosed are methods of administering BIRB 796 BS, a p38 MAPK inhibitor, at particular dosages.

Claims11

Dependent claims

A method of administering BIRB 796 BS to a patient in need of treatment of a cytokine mediated disease comprising administering BIRB 796 BS twice daily, each dosage being less than 150 mg of the active ingredient compound.

Dependencies are inferred from the claim text.

Facts

Application: 10/313,667Filed 6 Dec 2002
Priority: 11 Dec 2001
Published: 26 Jun 2003
Term ends: Not estimatedThe source records don’t support an estimate.

Classification27 codes

A61K 31/5377
1,4-Oxazines, e.g. morpholine: not condensed and containing further heterocyclic rings, e.g. timolol
A61P 1/00
Drugs for disorders of the alimentary tract or the digestive system
A61P 1/18
Drugs for disorders of the alimentary tract or the digestive system: for pancreatic disorders, e.g. pancreatic enzymes
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics

Family

Application60/339,249Us provisional application · filed 11 Dec 2001
US 2003/0118575 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results